Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
publishDate:"[2010 TO 2019]"
publishDate:"[2018 TO 2018]"
topic_facet:"Medical Condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) MedDRA version: 20.0Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864 MedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=publishDate%3A%22%5B2018+TO+2018%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Locally+Advanced+or+Metastatic+Non-Small+Cell+Lung+Cancer+%28Stage+IIIB-IV%29+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10066490Term%3A+Progression+of+non-small+cell+lung+cancerSystem+Organ+Class%3A+100000004864+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10029514Term%3A+Non-small+cell+lung+cancer+NOSSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
/vufind/Search/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=publishDate%3A%22%5B2018+TO+2018%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Locally+Advanced+or+Metastatic+Non-Small+Cell+Lung+Cancer+%28Stage+IIIB-IV%29+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10066490Term%3A+Progression+of+non-small+cell+lung+cancerSystem+Organ+Class%3A+100000004864+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10029514Term%3A+Non-small+cell+lung+cancer+NOSSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=publishDate%3A%22%5B2010+TO+2019%5D%22&filter%5B%5D=publishDate%3A%22%5B2018+TO+2018%5D%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Locally+Advanced+or+Metastatic+Non-Small+Cell+Lung+Cancer+%28Stage+IIIB-IV%29+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10066490Term%3A+Progression+of+non-small+cell+lung+cancerSystem+Organ+Class%3A+100000004864+MedDRA+version%3A+20.0Level%3A+LLTClassification+code+10029514Term%3A+Non-small+cell+lung+cancer+NOSSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject
PubPharm (8)
1
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - ARCTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
2
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - AstraZeneca D4191C00004 ARCTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
3
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - ARCTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
4
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - AstraZeneca D4191C00004 ARCTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
5
A Phase II Study of MEDI4736 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC) - ATLANTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
6
A Phase II Study of MEDI4736 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC) - ATLANTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
7
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - ARCTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
8
A Phase III Study of MEDI4736, given as Monotherapy or in Combination with Tremelimumab, versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer : A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) - ARCTIC
enthalten in:
WHO International Clinical Trials Registry Platform
| 2018
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Erscheinungsjahr: 2010-2019
Filter aufheben
Erscheinungsjahr: 2018-2018
Filter aufheben
Thema: Medical Condition: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) MedDRA version: 20.0Level: LLTClassification code 10066490Term: Progression of non-small cell lung cancerSystem Organ Class: 100000004864 MedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
8
Aufsätze
8
E-Artikel
8
E-Ressourcen
Zeitschriftentitel
8
WHO International Clinical Trials Registry Plat...
Thema
8
610
Medical Condition: Locally Advanced or Metastat...
8
Recruitment Status: Authorised-recruitment may ...
8
Study Type: Interventional
6
Phase: Phase 3
2
Phase: Phase 2
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2018-2018
Erscheinungsjahr(e)
Von:
Bis:
Sprache
8
Englisch
Haven't found what you're looking for?
Wird geladen...